NOVO NORDISK A/S | 132,00 Euro | -1,990 -1,49 % | |
| WKN: A0M9QL ISIN: DK0060102614 Ticker-Symbol: NOVB | Frankfurt | 21.05.13 | 17:29 Uhr |
Branche PharmaAktienmarkt OMX Copenhagen 20 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 22:13 | Positive Data on Novo Nordisk's N9-GP | 1 | Zacks | |
| 20.05. | Novo Nordisk reports positive results from Phase-3 haemophilia B study of N9-GP | 31 | Pharma Bus Review | |
| 17.05. | Novo Nordisk (NVO) Reports Positive Results from Paradigm 2 | 28 | StreetInsider.com | |
| 16.05. | Novo Nordisk and Paula Deen Announce Winners of the Seeing Diabetes in a New Light' Contest | 61 | PR Newswire | |
| PRINCETON, N.J., May 16, 2013 /PRNewswire/ --Novo Nordisk, the world leader in diabetes care, along with author, restaurateur and Food Network star Paula Deen, have selected six winners for their... Mehr lesen zu: Novo Nordisk and Paula Deen Announce Winners of the Seeing Diabetes in a New Light' Contest | ||||
| 08.05. | Novo Nordisk invests in Kalundborg plant for semaglutide production | 42 | Pharma Bus Review | |
| 07.05. | NOVO NORDISK A S - 6-K, Report of foreign issuer | 34 | SEC Filings | |
| 02.05. | Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcript | 54 | Seeking Alpha | |
| 01.05. | Novo Nordisk and EMIS Modify Deal | 20 | Zacks | |
| 01.05. | Novo Nordisk Posts 28% Rise In Q1 Profit, Lifts Forecast | 97 | Benzinga.com | |
| 01.05. | Danish drug maker Novo Nordisk Q1 net profits up 28 per cent on strong sales of diabetic drugs | 41 | Yahoo-CAN | |
| 01.05. | Emisphere, Novo Nordisk amend Oral GLP-1 development, license agreement | 20 | Pharma Bus Review | |
| 01.05. | Novo Nordisk Net Profit Up As Insulin Sales Surge | 31 | Euroinvestor | |
| 01.05. | Novo Nordisk First-Quarter Profit Climbs on Insulins, Victoza | 50 | Bloomberg | |
| 30.04. | NOVO NORDISK A S - 6-K, Report of foreign issuer | 23 | SEC Filings | |
| 24.04. | Kymab and Novo Nordisk sign Kymouse antibody discovery deal | 71 | Pharma Bus Review | |
| 22.04. | NASDAQ OMX Copenhagen A/S: Novo Nordisk A/S - reduction in share capital by cancelling own shares | 149 | GlobeNewswire | |
| Novo Nordisk A/S - reduction in share capital by cancelling own shares
The B share capital of the following share will be reduced on NASDAQ OMX
Copenhagen as per 25 April 2013.
On a general meeting... Mehr lesen zu: NASDAQ OMX Copenhagen A/S: Novo Nordisk A/S - reduction in share capital by cancelling own shares | ||||
| 22.04. | Kymab Announces Kymouse Antibody Discovery Agreement With Novo Nordisk | 95 | PR Newswire | |
| CAMBRIDGE, England, April 22, 2013 /PRNewswire/ --
Kymab, a monoclonal antibody biopharmaceutical company, announced today an agreement in therapeutic antibody discovery. Novo Nordisk has been granted... Mehr lesen zu: Kymab Announces Kymouse Antibody Discovery Agreement With Novo Nordisk | ||||
| 19.04. | Novo Nordisk Unveils New U.S. Headquarters | 98 | PR Newswire | |
| PLAINSBORO, N.J., April 19, 2013 /PRNewswire/ --Advancing its commitment to patients and New Jersey, Novo Nordisk (NYSE: NVO) today unveiled its new U.S. headquarters. Located in Mercer County in... Mehr lesen zu: Novo Nordisk Unveils New U.S. Headquarters | ||||
| 19.04. | Zacks Bull and Bear of the Day Highlights: Grupo Aeroportuario del Centro Norte, Titan Machinery, Eli Lilly,Novo Nordisk and Bristol-Myers Squibb | 142 | PR Newswire | |
| CHICAGO, April 19, 2013 /PRNewswire/ --Zacks Equity Research highlights Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (Nasdaq:OMAB) as the Bull of the Day and Titan Machinery Inc.... Mehr lesen zu: Zacks Bull and Bear of the Day Highlights: Grupo Aeroportuario del Centro Norte, Titan Machinery, Eli Lilly,Novo Nordisk and Bristol-Myers Squibb | ||||
| 18.04. | Bearish Moving Average Cross by Novo Nordisk | 46 | SmarTrend | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| NOVARTIS | 57,86 | -0,10 % | Gericht prüft Klage von Pharmakonzern Novartis gegen Bewertung |
| PFIZER | 21,975 | -1,70 % | Pfizer Stops Lymphoma Drug Late-Stage Trial Due To Ineffectiveness |
| GILEAD SCIENCES | 43,641 | +0,49 % | Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) |
| SANOFI | 84,78 | +0,95 % | S&P Equity hebt Ziel für Sanofi auf 92 Euro - 'Buy' |
| GLAXOSMITHKLINE | 20,425 | +0,37 % | Berenberg hebt Ziel für GlaxoSmithKline auf 1.870 Pence - 'Buy' |
